Following this activation, TANK-binding kinase 1 (TBK1) and IRF3 are phosphorylated, leading to type I IFNs and inflammatory agents, all of which contribute to the tumor immune response (Figure 2) [59,60]. The gene discussed is TBK1; the disease is neoplasm.